MedTrace Logo

Reactogenicity Study of Cervarix and Gardasil in UK Adolescent Girls

NCT00956553 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 400

Last updated 2020-10-01

No results posted yet for this study

Summary

This is a phase IV study to evaluate the body's immune response of participants to the Cervarix and Gardasil vaccines against the Human Papilloma Virus (HPV) types associated with increased risk of cervical cancer.

Conditions

  • HPV Infections

Interventions

BIOLOGICAL

Cervarix

Three doses of Cervarix at month 0, 1 and 6.

BIOLOGICAL

Gardasil

Three doses of Gardasil at month 0, 1 and 6.

Sponsors & Collaborators

  • Public Health England

    lead OTHER_GOV

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
13 Years
Max Age
15 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-09-30
Primary Completion
2012-09-30
Completion
2013-09-30

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00956553 on ClinicalTrials.gov